These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 29248266)
21. Impact of 13-Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Carriage Rates of Streptococcus pneumoniae in a Rural Community in the Dominican Republic. Dunn MG; Lessa FC; Sánchez J; Cordero R; Feris-Iglesias J; Cedano D; Carvalho MDG; Fernández J; Feemster KA J Infect Dis; 2021 Sep; 224(12 Suppl 2):S237-S247. PubMed ID: 34469551 [TBL] [Abstract][Full Text] [Related]
22. Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible Streptococcus pneumoniae. Dagan R; Juergens C; Trammel J; Patterson S; Greenberg D; Givon-Lavi N; Porat N; Gurtman A; Gruber WC; Scott DA J Infect Dis; 2015 Apr; 211(7):1144-53. PubMed ID: 25355940 [TBL] [Abstract][Full Text] [Related]
23. Pneumococcal nasopharyngeal carriage in children <5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel. Ben-Shimol S; Givon-Lavi N; Greenberg D; Dagan R Hum Vaccin Immunother; 2016; 12(2):268-76. PubMed ID: 26430921 [TBL] [Abstract][Full Text] [Related]
24. The impact of pneumococcal conjugate vaccines on serotype 19A nasopharyngeal carriage. Tin Tin Htar M; Sings HL; Syrochkina M; Taysi B; Hilton B; Schmitt HJ; Gessner BD; Jodar L Expert Rev Vaccines; 2019 Dec; 18(12):1243-1270. PubMed ID: 31587592 [No Abstract] [Full Text] [Related]
25. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination. Wysocki J; Brzostek J; Szymański H; Tetiurka B; Toporowska-Kowalska E; Wasowska-Królikowska K; Sarkozy DA; Giardina PC; Gruber WC; Emini EA; Scott DA Vaccine; 2015 Mar; 33(14):1719-25. PubMed ID: 25698485 [TBL] [Abstract][Full Text] [Related]
26. The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial. Dagan R; Givon-Lavi N; Porat N; Greenberg D Vaccine; 2012 Jul; 30(34):5132-40. PubMed ID: 22683519 [TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Peterson JT; Stacey HL; MacNair JE; Li J; Hartzel JS; Sterling TM; Benner P; Tamms GM; Musey LK Hum Vaccin Immunother; 2019; 15(3):540-548. PubMed ID: 30427749 [TBL] [Abstract][Full Text] [Related]
28. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults. Stacey HL; Rosen J; Peterson JT; Williams-Diaz A; Gakhar V; Sterling TM; Acosta CJ; Nolan KM; Li J; Pedley A; Benner P; Abeygunawardana C; Kosinski M; Smith WJ; Pujar H; Musey LK Hum Vaccin Immunother; 2019; 15(3):530-539. PubMed ID: 30648919 [TBL] [Abstract][Full Text] [Related]
29. Pneumococcal antibody concentrations and carriage of pneumococci more than 3 years after infant immunization with a pneumococcal conjugate vaccine. Akinsola AK; Ota MO; Enwere GC; Okoko BJ; Zaman SM; Saaka M; Nsekpong ED; Odutola AA; Greenwood BM; Cutts FT; Adegbola RA PLoS One; 2012; 7(2):e31050. PubMed ID: 22363544 [TBL] [Abstract][Full Text] [Related]
30. Measuring the effects of pneumococcal conjugate vaccine (PCV7) on Streptococcus pneumoniae carriage and antibiotic resistance: the Palestinian-Israeli Collaborative Research (PICR). Daana M; Rahav G; Hamdan A; Thalji A; Jaar F; Abdeen Z; Jaber H; Goral A; Huppert A; Raz M; Regev-Yochay G; Vaccine; 2015 Feb; 33(8):1021-6. PubMed ID: 25593104 [TBL] [Abstract][Full Text] [Related]
31. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children. Thanee C; Pancharoen C; Likitnukul S; Luangwedchakarn V; Umrod P; Phasomsap C; Apornpong T; Chuanchareon T; Butterworth O; Puthanakit T Vaccine; 2011 Aug; 29(35):5886-91. PubMed ID: 21729732 [TBL] [Abstract][Full Text] [Related]
32. Dynamics and Determinants of Pneumococcal Antibodies Specific against 13 Vaccine Serotypes in the Pre-Vaccination Era. Prins-van Ginkel AC; Berbers GA; Grundeken LH; Tcherniaeva I; Wittenberns JI; Elberse K; Mollema L; de Melker HE; Knol MJ PLoS One; 2016; 11(1):e0147437. PubMed ID: 26796783 [TBL] [Abstract][Full Text] [Related]
33. Epidemiological and molecular characterization of Streptococcus pneumoniae carriage strains in pre-school children in Arkhangelsk, northern European Russia, prior to the introduction of conjugate pneumococcal vaccines. Vorobieva S Jensen V; Furberg AS; Slotved HC; Bazhukova T; Haldorsen B; Caugant DA; Sundsfjord A; Valentiner-Branth P; Simonsen GS BMC Infect Dis; 2020 Apr; 20(1):279. PubMed ID: 32293324 [TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis. Feng S; McLellan J; Pidduck N; Roberts N; Higgins JP; Choi Y; Izu A; Jit M; Madhi SA; Mulholland K; Pollard AJ; Procter S; Temple B; Voysey M Health Technol Assess; 2024 Jul; 28(34):1-109. PubMed ID: 39046101 [TBL] [Abstract][Full Text] [Related]
35. Prevalence of pneumococcal nasopharyngeal colonization and serotypes circulating in Cameroonian children after the 13-valent pneumococcal conjugate vaccine introduction. Njuma Libwea J; Gröndahl-Yli-Hannuksela K; Kobela M; Toropainen M; Nyholm O; Ndombo PK; Koulla-Shiro S; Nohynek H; Nuorti JP; Vuopio J; Palmu AA Int J Infect Dis; 2020 Sep; 98():113-120. PubMed ID: 32562849 [TBL] [Abstract][Full Text] [Related]
36. Pneumococcal conjugate vaccine-elicited antibody persistence and immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously vaccinated with 4 doses of either 7-valent or 13-valent pneumococcal conjugate vaccine. Quinet B; Laudat F; Gurtman A; Patterson S; Sidhu M; Gruber WC; Scott DA Pediatr Infect Dis J; 2014 Oct; 33(10):1065-76. PubMed ID: 25093973 [TBL] [Abstract][Full Text] [Related]
37. Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children. Tocheva AS; Jefferies JM; Rubery H; Bennett J; Afimeke G; Garland J; Christodoulides M; Faust SN; Clarke SC Vaccine; 2011 Jun; 29(26):4400-4. PubMed ID: 21504773 [TBL] [Abstract][Full Text] [Related]
38. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study. De Montalembert M; Abboud MR; Fiquet A; Inati A; Lebensburger JD; Kaddah N; Mokhtar G; Piga A; Halasa N; Inusa B; Rees DC; Heath PT; Telfer P; Driscoll C; Al Hajjar S; Tozzi A; Jiang Q; Emini EA; Gruber WC; Gurtman A; Scott DA Pediatr Blood Cancer; 2015 Aug; 62(8):1427-36. PubMed ID: 25810327 [TBL] [Abstract][Full Text] [Related]
39. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults. Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785 [TBL] [Abstract][Full Text] [Related]
40. Effect of previous vaccination with pneumococcal conjugate vaccine on pneumococcal polysaccharide vaccine antibody responses. Schaballie H; Wuyts G; Dillaerts D; Frans G; Moens L; Proesmans M; Vermeulen F; De Boeck K; Meyts I; Bossuyt X Clin Exp Immunol; 2016 Aug; 185(2):180-9. PubMed ID: 26939935 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]